# GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies

> **NCT04824794** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genmab** · enrollment: 130 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma (RRMM)
- Diffuse Large B Cell Lymphoma (DLBCL)
- Acute Myeloid Leukemia (AML)

## Interventions

- **BIOLOGICAL:** GEN3014
- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT04824794
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-09
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-07-31
- **Target enrollment:** 130 (ACTUAL)
- **Why stopped:** The sponsor has decided to discontinue further development of GEN3014 after a comprehensive review of the data, market landscape, and strategic priorities.
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04824794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04824794, "GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04824794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*